Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 3;7(7):CD012380.
doi: 10.1002/14651858.CD012380.pub2.

Interventions for chronic kidney disease in people with sickle cell disease

Noemi Ba Roy  1 , Patricia M Fortin, Katherine R Bull, Carolyn Doree, Marialena Trivella, Sally Hopewell, Lise J Estcourt
Affiliations

Interventions for chronic kidney disease in people with sickle cell disease

Noemi Ba Roy et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Sickle cell disease (SCD) is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta-globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD.Chronic kidney disease is defined as abnormalities of kidney structure or function, present for more than three months. Sickle cell nephropathy refers to the spectrum of kidney complications in SCD.Glomerular damage is a cause of microalbuminuria and can develop at an early age in children with SCD, and increases in prevalence in adulthood. In people with sickle cell nephropathy, outcomes are poor as a result of the progression to proteinuria and chronic kidney insufficiency. Up to 12% of people who develop sickle cell nephropathy will develop end-stage renal disease.

Objectives: To assess the effectiveness of any intervention in preventing or reducing kidney complications or chronic kidney disease in people with SCD (including red blood cell transfusions, hydroxyurea and angiotensin-converting enzyme inhibitor (ACEI)), either alone or in combination with each other.

Search methods: We searched for relevant trials in the Cochrane Library, MEDLINE (from 1946), Embase (from 1974), the Transfusion Evidence Library (from 1980), and ongoing trial databases; all searches current to 05 April 2016. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register: 13 April 2017.

Selection criteria: Randomised controlled trials comparing interventions to prevent or reduce kidney complications or chronic kidney disease in people with SCD. There were no restrictions by outcomes examined, language or publication status.

Data collection and analysis: Two authors independently assessed trial eligibility, extracted data and assessed the risk of bias.

Main results: We included two trials with 215 participants. One trial was published in 2011 and included 193 children aged 9 months to 18 months, and compared treatment with hydroxyurea to placebo. The second trial was published in 1998 and included 22 adults with normal blood pressure and microalbuminuria and compared ACEI to placebo.We rated the quality of evidence as low to very low across different outcomes according to GRADE methodology. This was due to trials having: a high or unclear risk of bias including attrition and detection bias; indirectness (the available evidence was for children aged 9 months to 18 months in one trial and a small and select adult sample size in a second trial); and imprecise outcome effect estimates of significant benefit or harm. Hydroxyurea versus placebo We are very uncertain if hydroxyurea reduces or prevents progression of kidney disease (assessed by change in glomerular filtration rate), or reduces hyperfiltration in children aged 9 to 18 months, mean difference (MD) 0.58 (95% confidence interval (CI) -14.60 to 15.76 (mL/min per 1.73 m²)) (one study; 142 participants; very low-quality evidence).In children aged 9 to 18 months, hydroxyurea may improve the ability to concentrate urine, MD 42.23 (95% CI 12.14 to 72.32 (mOsm/kg)) (one study; 178 participants; low-quality evidence).Hydroxyurea may make little or no difference to SCD-related serious adverse events including: incidence of acute chest syndrome, risk ratio (RR) 0.39 (99% CI 0.13 to 1.16); painful crisis, RR 0.68 (99% CI 0.45 to 1.02); and hospitalisations, RR 0.83 (99% CI 0.68 to 1.01) (one study, 193 participants; low-quality evidence).No deaths occurred in the trial. Quality of life was not reported. ACEI versus placeboWe are very uncertain if ACEI reduces proteinuria in adults with SCD who have normal blood pressure and microalbuminuria, MD -49.00 (95% CI -124.10 to 26.10 (mg per day)) (one study; 22 participants; very low-quality evidence). We are very uncertain if ACEI reduce or prevent kidney disease as measured by creatinine clearance. The authors state that creatinine clearance remained constant over six months in both groups, but no comparative data were provided (very low-quality evidence).All-cause mortality, serious adverse events and quality of life were not reported.

Authors' conclusions: In young children aged 9 months to 18 months, we are very uncertain if hydroxyurea improves glomerular filtration rate or reduces hyperfiltration, but it may improve young children's ability to concentrate urine and may make little or no difference on the incidence of acute chest syndrome, painful crises and hospitalisations.We are very uncertain if giving ACEI to adults with normal blood pressure and microalbuminuria has any effect on preventing or reducing kidney complications.This review identified no trials that looked at red cell transfusions nor any combinations of interventions to prevent or reduce kidney complications.Due to lack of evidence this review cannot comment on the management of either children aged over 18 months or adults with any known genotype of SCD.We have identified a lack of adequately-designed and powered studies, and no ongoing trials which address this critical question. Trials of hydroxyurea, ACEI or red blood cell transfusion in older children and adults are urgently needed to determine any effect on prevention or reduction kidney complications in people with SCD.

PubMed Disclaimer

Conflict of interest statement

Noemi Roy: none known.

Patricia Fortin: funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Katherine Bull: none known.

Carolyn Doree: none known.

Sally Hopewell: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Marialena Trivella: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Lise Estcourt: partly funded by the NIHR Cochrane Programme Grant ‐ Safe and Appropriate Use of Blood Components.

Figures

1
1
Sickle cell nephropathy pathophysiology in sickle cell disease: Adapted fromOkafor 2013andNath 2015 RBC: red blood cells; FSGS: focal segmental glomerulosclerosis; ESRD: end‐stage renal disease
2
2
Structure of the kidney. From: Wikispaces. Human Physiology. 12. Urology.https://humanphysiology2011.wikispaces.com/12.+Urology
3
3
Study flow diagram.
4
4
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
5
5
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 1 Slower progression or improvement in GFR (mL per min per 1·73 m²).
1.2
1.2. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 2 Improvement in ability to concentrate urine (mOsm/kg).
1.3
1.3. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 3 SAEs assessed with acute chest syndrome.
1.4
1.4. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 4 SAEs assessed with painful crisis.
1.5
1.5. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 5 SAEs assessed with hospitalisations.
1.6
1.6. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 6 SAEs assessed with stroke.
1.7
1.7. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 7 AEs assessed with neutropenia.
1.8
1.8. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 8 AEs assessed with thrombocytopenia.
1.9
1.9. Analysis
Comparison 1 Hydroxyurea vs placebo, Outcome 9 Number of participants transfused.
2.1
2.1. Analysis
Comparison 2 ACEI (captopril) vs placebo, Outcome 1 Slower progression or reduction in proteinuria (mg/day).
2.2
2.2. Analysis
Comparison 2 ACEI (captopril) vs placebo, Outcome 2 Other drug‐related adverse events (dry cough).
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

BABY HUG 2011 {published data only}
    1. Adams RJ, Barredo J, Bonds DR, Brown C, Casella J, Daner L, et al. TCD in infants: A report from the BABY HUG trial. Blood 2005; Vol. 106, issue 11. [Abstract no: 952; CENTRAL: 593091; CRS: 5500100000003045]
    1. Adams RJ, Luden J, Miller S, Wang W, Rees R, Li D, et al. TCD in infants: a report from the Baby Hug study. 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9‐13; Cincinnati, Ohio.. 2005:105. [CENTRAL: 592981; CRS: 5500100000002944]
    1. Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi‐center placebo‐controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood & Cancer 2012;59(4):668‐74. [CENTRAL: 848700; CRS: 5500125000000525; PUBMED: 22294512] - PMC - PubMed
    1. Armstrong FD, Elkin TD, Brown RC, Glass P, Rana S, Casella JF, et al. Developmental function in toddlers with sickle cell anemia. Pediatrics 2013;131(2):e406‐14. [CENTRAL: 853612; CRS: 5500125000000530; PUBMED: 23296434] - PMC - PubMed
    1. Armstrong FD, Elkin TD, Brown RC, Glass P, Rees RC, Wang WC, et al. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial. Blood 2008; Vol. 112, issue 11. [Abstract no: 713; CENTRAL: 723732; CRS: 5500100000003393]
Foucan 1998 {published data only}
    1. Foucan L, Bourhis V, Bangou J, Merault L, Etienne‐Julan M, Salmi RL. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. American Journal of Medicine 1998;104(4):339‐42. - PubMed

References to studies excluded from this review

Jain 2012 {published data only}
    1. Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A. Low fixed‐dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin 2012;36(4):323‐32. - PubMed
NCT02373241 {published data only}
    1. NCT02373241. Preventing sickle cell kidney disease [Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease]. clinicaltrials.gov/ct2/show/NCT02373241 Date first received: 5 February 2015.
Steinberg 2003 {published data only}
    1. Steinberg MH, Barton F, Castro, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and Morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289(13):1645‐51. - PubMed

References to ongoing studies

NCT01732718 {published data only}
    1. NCT01732718. Effect of atorvastatin on endothelial dysfunction and albuminuria in sickle cell disease (ENDO) [The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)]. clinicaltrials.gov/ct2/show/NCT01732718 Date first received: 9 November 2012.

Additional references

Adam 2008
    1. Adam S, Jonassaint J, Kruger H, Kail M, Orringer EP, Eckman JR, et al. Surgical and obstetric outcomes in adults with sickle cell disease. American Journal of Medicine 2008;121(10):916‐21. - PMC - PubMed
Akinsheye 2011
    1. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin C T, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118(1):19‐27. - PMC - PubMed
Alvarez 2006
    1. Alvarez O, Montane B, Lopez G, Wilkinson J, Miller T. Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatric Blood & Cancer 2006;47:71‐6. - PubMed
Alvarez 2012
    1. Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi‐center placebo‐controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood & Cancer 2012;59(4):668‐74. - PMC - PubMed
Arlet 2012
    1. Arlet JB, Ribeil JA, Chatellier G, Eladari D, Seigneux S, Souberbielle JC, et al. Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: a prospective observational cohort study. BMC Nephrology 2012;13:83. - PMC - PubMed
Asnani 2013
    1. Asnani MR, Lynch O, Reid ME. Determining glomerular filtration rate in Homozygous sickle cell disease: Utility of serum creatinine based estimating equations. PLoS ONE 2013;8(7):e69922. - PMC - PubMed
Asnani 2015
    1. Asnani MR, Reid ME. Renal function in adult Jamaicans with homozygous sickle cell disease. Hematology 2015;20(7):422‐8. - PubMed
Astor 2011
    1. Astor BC, Matsushita K, Gansevoort RT, Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end‐stage renal disease. A collaborative meta‐analysis of kidney disease population cohorts. Kidney International 2011; Vol. 79, issue 12:1331‐40. - PMC - PubMed
Ataga 2014
    1. Ataga KI, Derebail VK, Archer DR. The glomerulopathy of sickle cell disease. American Journal of Hematology 2014;89:907‐14. - PMC - PubMed
Aygun 2013
    1. Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. American Journal of Hematology 2013;88(2):116‐9. - PMC - PubMed
Botev 2009
    1. Botev R, Mallie´ JP, Couchoud C, Schuck O, Fauvel JP, Wetzels JFM, et al. Estimating glomerular filtration rate: Cockcroft–Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clinical Journal of the American Society of Nephrology 2009;4(5):899‐906. - PMC - PubMed
Boyle 2016
    1. Boyle SM, Jacobs B, Sayani FA, Hoffman B. Management of the dialysis patient with sickle cell disease. Seminars in Dialysis 2016;29(1):62‐70. - PubMed
Brun 2003
    1. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea down regulates endothelin‐1 gene expression and up regulates ICAM‐1 gene expression in cultured human endothelial cells. Pharmacogenomics Journal 2003;3(4):215‐26. - PubMed
Charache 1995
    1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 1995;332(20):1317‐22. - PubMed
Chou 2013a
    1. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology / the Education Program of the American Society of Hematology 2013;2013(1):439‐46. - PubMed
Chou 2013b
    1. Chou ST, Jackson T, Vege S, Smith‐Whitley K, Friedman DF, Whesthoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh‐matched minority donors. Blood 2013;122(6):1062‐71. - PubMed
Covidence 2015 [Computer program]
    1. Veritas Health Innovation. Covidence systematic review software. Version accessed prior to 12 April 2017. Melbourne, Australia: Veritas Health Innovation, 2015.
de Zeeuw 2004
    1. Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney International. Supplement 2004;92:S2‐6. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Field 2014
    1. Field JJ, Nathan DG. Advances in sickle cell therapies in the hydroxyurea era. Molecular Medicine 2014;20 Suppl 1:S37‐42. - PMC - PubMed
Frenette 2007
    1. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. Journal of Clinical Investigation 2007;117(4):850‐8. - PMC - PubMed
Gansevoort 1995
    1. Gansevoort RT, Sluiter WJ, Hemmelder MH, Zeeuw D, Jong PE. Antiproteinuric effect of blood‐pressure‐lowering agents: a meta‐analysis of comparative trials. Nephrology, Dialysis, Transplantation 1995;10(11):1963‐74. - PubMed
Gaspari 2006
    1. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. American Journal of Kidney Diseases 2006;47(1):1‐7. - PubMed
Gosmanova 2014
    1. Gosmanova EO, Zaidi S, Wan JY, Adams‐Graves PE. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. Journal of Investigative Medicine 2014;62(5):804‐7. - PubMed
Gravitz 2014
    1. Gravitz L, Pincock S. Sickle‐cell disease. Nature 2014;515(7526):S1. - PubMed
Grosse 2011
    1. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine 2011;41(6 Suppl 4):S398‐405. - PMC - PubMed
Hamideh 2013
    1. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999–2009). Blood Cancer 2013;60(9):1482‐86. - PubMed
Haymann 2010
    1. Haymann JP, Stankovic K, Levy P, Avellino V, Tharaux PL, Letavernier E, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clinical Journal of the American Society of Nephrology 2010;5(5):756‐61. - PMC - PubMed
Hebbel 2014
    1. Hebbel RP. Ischemia‐reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematology/oncology clinics of North America 2014;28(2):181‐98. - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC, editor(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011c
    1. Higgins JPT, Deeks JJ, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hillery 2000
    1. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British Journal of Haematology 2000;109(2):322‐7. - PubMed
Howard 2015
    1. Howard J, Hart N, Roberts‐Harewood M, Cummins M, Awogbade M, Davis B. Guideline on the management of acute chest syndrome in sickle cell disease. British Journal of Haematology 2015;169(4):492‐505. - PubMed
Kato 2006a
    1. Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology 2006;81(7):503‐10. - PMC - PubMed
Kato 2006b
    1. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis‐associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107(6):2279‐85. - PMC - PubMed
KDIGO 2012
    1. National Kidney Foundation. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 2013; Vol. 3, issue 1:1‐163. - PubMed
Lebensburger 2011
    1. Lebensburger J, Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. American Journal of Hematology 2011;86(5):430‐2. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Levey 1999
    1. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. Journal of the American Society of Nephrology 1999;10(11):2426‐39. - PubMed
Levey 2009
    1. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009;150(9):604‐12. - PMC - PubMed
Lewis 1993
    1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine 1993;329(20):1456‐62. - PubMed
Macconi 2006
    1. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, et al. Permselective dysfunction of podocyte‐podocyte contact upon angiotensin II unravels the molecular tTarget for renoprotective iIntervention. American Journal of Pathology 2006;168(4):1073‐85. - PMC - PubMed
Maki 1995
    1. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long‐term effects of antihypertensive agents on proteinuria and renal function. Archives of Internal Medicine 1995;155(10):1073‐80. - PubMed
Marsenic 2008
    1. Marsenic O, Couloures KG, Wiley JM. Proteinuria in children with sickle cell disease. Nephrology, Dialysis, Transplantation 2008;23(2):715‐20. - PubMed
McKie 2007
    1. McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. Journal of Pediatric Hematology/Oncology 2007;29(3):140‐4. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐Analyses:The PRISMA Statement. Annals of Internal Medicine 2009;151(4):264‐9. - PubMed
Nasr 2006
    1. Nasr SH, Markowitz GS, Sentman RL, D'Agati VD. Sickle cell disease, nephrotic syndrome, and renal failure. Kidney International 2006;69(7):1276‐80. - PubMed
Nath 2015
    1. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nature Reviews. Nephrology 2015;11(3):161‐71. - PMC - PubMed
NICE 2010
    1. National Institute for Health and Care Excellence. Clinical knowledge summaries: Sickle cell disease. cks.nice.org.uk/sickle‐cell‐disease#!backgroundsub:3. London: NICE, (accessed 15 August 2016).
Okafor 2013
    1. Okafor UH, Aneke E. Outcome and challenges of kidney transplant in patients with sickle cell disease. Journal of Transplantation 2013;2013:614610. - PMC - PubMed
Parmar 1998
    1. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Piel 2012
    1. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model‐based map and population estimates. Lancet 2012;381(9861):142‐51. - PMC - PubMed
Pleasants 2014
    1. Pleasants S. Epidemiology: a moving target. Nature 2014;515(7526):S2‐3. - PubMed
Porter 2013
    1. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. ASH Education Program Book 2013;1:447‐56. [DOI: 10.1182/asheducation-2013.1.447] - DOI - PubMed
Potoka 2015
    1. Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. American Journal of Physiology. Lung Cellular and Molecular Physiology 2015;308(4):L314‐24. - PMC - PubMed
Powars 2005
    1. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4‐decade observational study of 1056 patients. Medicine 2005;84(6):363‐76. - PubMed
Pule 2015
    1. Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A systematic review of known mechanisms of hydroxyurea‐induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 2015;8(5):669‐79. - PMC - PubMed
Rees 2010
    1. Rees DC, Williams TN, Gladwin MT. Sickle‐cell disease. Lancet 2010;376(9757):2018‐31. - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rumaney 2014
    1. Rumaney MB, Ngo Bitoungui VJ, Vorster AA, Ramesar R, Kengne AP, Ngogang J, et al. The co‐inheritance of alpha‐thalassemia and sickle cell anemia Is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS ONE 2014;9:e100516. - PMC - PubMed
Sandhu 2015
    1. Sandhu MK, Cohen A. Aging in sickle cell disease: co‐morbidities and new issues in management. Hemoglobin 2015;39(4):221‐4. - PubMed
Sasongko 2015
    1. Sasongko TH, Nagalla S, Ballas SK. Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD009191.pub3] - DOI - PMC - PubMed
Scheunemann 2010
    1. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. American Journal of the Medical Sciences 2010;339(3):266‐9. - PMC - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editor(s). Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Schünemann 2011b
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sealed Envelope [Computer program]
    1. Sealed Envelope Ltd. Power calculator for binary outcome superiority trial. Available from: https://www.sealedenvelope.com/power/binary‐superiority. Version accessed 06 February 2017. Sealed Envelope Ltd, 2012.
Sharpe 2014
    1. Sharpe CC, Thein SL. How I treat renal complications in sickle cell disease. Blood 2014;123(24):3720‐6. - PubMed
Sparkenbaugh 2013
    1. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology 2013;162(1):3‐14. - PMC - PubMed
Steinberg 2012
    1. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American Journal of Hematology 2012;87(8):795‐803. - PMC - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D, editor(s) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Styles 1997
    1. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, et al. Decrease of very late activation antigen‐4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89(7):2554‐9. - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. [DOI: 10.1186/1745-6215-8-16] - DOI - PMC - PubMed
Ubesie 2012
    1. Ubesie A, Emodi I, Ikefuna A, Ilechukwu G, Ilechukwu G. Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research 2012;2(2):109‐13. - PMC - PubMed
van der Meer 2010
    1. Meer IM, Cravedi P, Remuzzi G. The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis & Tissue Repair 2010;3:7. [DOI: 10.1186/1755-1536-3-7] - DOI - PMC - PubMed
Ventura 1985
    1. Ventura HO, Frohlich ED, Messerli FH, Kobrin I, Kardon MB. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. American Journal of Cardiology 1985;55(8):1023‐6. - PubMed
Wang 2011
    1. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle‐cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663‐72. - PMC - PubMed
Yawn 2014
    1. Yawn BP, Buchanan GR, Afenyi‐Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: Summary of the 2014 evidence‐based report by expert panel members. JAMA 2014;312(10):1033‐48. - PubMed
Yazdanbakhsh 2012
    1. Yazdanbakhsh K, Ware RE, Noizat‐Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012;120(3):528‐37. - PMC - PubMed
Yee 2011
    1. McPherson Yee M, Jabbar SF, Osunkwo I, Clement L, Lane PA, Eckman JR, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clinical Journal of The American Society of Nephrology 2011;6(11):2628‐33. - PMC - PubMed
Zafrani 2015
    1. Zafrani L, Ince C. Microcirculation in acute and chronic kidney diseases. American Journal of Kidney Diseases 2015;66(6):1083‐94. - PubMed
Ziyadeh 2008
    1. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Current Diabetes Reviews 2008;4(1):39‐45. - PubMed

Publication types

MeSH terms